GlassScriptPhysician profile
Jeffrey T Najor
NPI 1124381827
$20,017.75
in general payments reported to CMS, 2019-2025
56 companies · $4,641 in 2025
The $4,641 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $563 · 2021: $1,741 · 2022: $2,709 · 2023: $4,221 · 2024: $5,265 · 2025: $4,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,126.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,626.81 | 2021-2025 | |
| Pfizer INC. | $1,675.10 | 2019-2025 | |
| Novo Nordisk INC | $1,226.23 | 2020-2025 | Wegovy, Saxenda, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,063.71 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $1,059.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lundbeck LLC | $1,004.44 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $826.84 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $814.02 | 2022-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Gilead Sciences, INC. | $713.43 | 2022-2025 | Descovy |
| Axsome Therapeutics, INC. | $704.81 | 2022-2025 | Auvelity |
| Shield Therapeutics INC | $677.62 | 2022-2025 | Accrufer |
| Alkermes, INC. | $654.31 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $629.57 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $605.19 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $578.05 | 2019-2025 | Trintellix |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Najor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.